Results 151 to 160 of about 16,654 (233)

Optical coherence tomography assessment of the impact of colchicine on non-culprit coronary plaque composition after myocardial infarction

Aims Low-dose colchicine reduces the risk of cardiovascular events after myocardial infarction (MI). The purpose of this study was to assess the effect of colchicine post-MI on coronary plaque morphology in non-culprit segments by optical coherence ...
Bursill, CA, Nguyen, MT, Dautov, R, Wong, DTL, Alcock, R, Salagaras, T, Sinhal, A, Marathe, JA, Montarello, NJ, Psaltis, PJ, Patel, S, Rajendran, S, Barlis, P, Nidorf, SM, Singh, K, et al.   +15 more
core   +1 more source

Variations in the Management of Uncontrolled Gout Between Rheumatologists and Nephrologists: A Retrospective Medical Record Review

ACR Open Rheumatology, Volume 8, Issue 9, September 2026.
Objective To evaluate the management practices of rheumatologists and nephrologists in treating patients with uncontrolled gout. Methods US board‐certified rheumatologists and nephrologists treating patients with uncontrolled gout participated in a web‐based, retrospective medical record audit study, sharing their perceptions of uncontrolled gout ...
Kenneth Saag, Nana Kragh, Amod Athavale, Bhavisha Desai, Amal Gulaid, Abiola Oladapo, Brittany Smith, Hyon Choi   +7 more
wiley   +1 more source

Clinical Phenotypes, Treatment, and Outcomes of Rheumatic Immune–Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitors: A Rheumatologists‐Referred Multicenter German Registry Cohort

ACR Open Rheumatology, Volume 8, Issue 9, September 2026.
Objective Immune checkpoint inhibitors (ICIs) induce a broad range of immune‐related adverse events (irAEs), including rheumatic manifestations. Evidence from dedicated rheumatology cohorts on the clinical spectrum, severity, treatment, and outcomes of rheumatic irAEs (rh‐irAEs) remains limited.
Didzis Gailis, Fabian T.H. Ullrich, Sophia Dombret, Marc Schmalzing, Rebecca Hasseli‐Fräbel, Torsten Witte, Thea Thiele, Uta Kiltz, Mara Oleszowsky, Marcel Müller, Karolina Gente, Christof Specker, Matthias B. Thaler, Alla Skapenko, Hendrik Schulze‐Koops   +14 more
wiley   +1 more source

Dysregulation of Peripheral Blood B Cells and Natural Killer Cells Is Associated With Myocarditis in Idiopathic Inflammatory Myopathies

ACR Open Rheumatology, Volume 8, Issue 9, September 2026.
Objective Idiopathic inflammatory myopathies (IIMs), or myositis, are a group of systemic autoimmune diseases leading to proximal muscle weakness. Myocarditis is a major cause of adverse outcomes. Yet, we know very little about the underlying immunologic processes that are driving myocarditis in the context of IIMs. Methods We performed single‐cell RNA
Carolina Duque, Sylvie T. Rousseau, Zuzana Bologna, Monica R. Mugnier, Luigi Adamo, Julie J. Paik   +5 more
wiley   +1 more source

Colchicine in renal diseases: Present and future

, 2018
Colchicine is a lipophilic alkaloid drug, which exhibits ant-inflammatory and anti-fibrotic properties. Cardinal mechanisms of action of colchicine are the disruption of the microtubule system and the inhibition of neutrophil adhesion and recruitment ...
Skalioti, C., Marinaki, S., Boletis, J.N.   +2 more
core  

Membrane Fusion‐Mediated Cytosolic Delivery of Threose Nucleic Acids via Homotypic Nanoparticles Overcomes Drug Resistance in Triple‐Negative Breast Cancer

Advanced Science, Volume 13, Issue 50, 7 September 2026.
This study introduces a biomimetic “nanofusion” platform that integrates the biostability of threose nucleic acids (TNA) with homotypic cell‐membrane cloaking to combat drug‐resistant TNBC. By leveraging a non‐canonical membrane‐fusion pathway for direct cytosolic delivery, the platform bypasses endosomal sequestration. To achieve potent AKT2 silencing
Wei Zheng, Tristan Juin Han Chang, Xinchao Li, Zhongqi Zhou, Chung Tin, Kenward Vong, Pierre Karam, Pik Kwan Lo   +7 more
wiley   +1 more source

Biomimetic Macrophage Cell Membrane‐Based Nanoparticles for Effective Treatment of Glioblastoma Through Boron Neutron Capture Therapy Combined With Immunotherapy

Advanced Science, Volume 13, Issue 52, 18 September 2026.
ABSTRACT Glioblastoma multiforme (GBM) remains largely incurable due to the blood‐brain barrier (BBB) and immunosuppressive microenvironment. While boron neutron capture therapy (BNCT) selectively eradicates tumor cells via 10B(n, α)‐7Li reactions, its clinical potential in GBM is unrealized because of the suboptimal pharmacokinetics of conventional ...
Jiawen Chen, Haoyu You, Hefa Huang, Huihui Chai, Ruize Zhu, Yun Guan, Qisheng Tang, Tianwen Li, Shan Jiang, Houshi Xu, Peng Wang, Yue Wang, Maoyuan Sun, Beining Liu, Zhen Li, Yulai Zeng, Weiqiu Ping, Yanlin Teng, Songlin Yan, Qinghui Li, Long Gu, Tao Sun, Zhifeng Shi   +22 more
wiley   +1 more source

Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents

American Journal of Hematology, Volume 101, Issue 9, Page 2166-2176, September 2026.
ABSTRACT Hypomethylating agents (HMA) and allogeneic hematopoietic stem cell transplantation (alloHSCT) have both demonstrated remissions in VEXAS; however, comparative data is lacking. We conducted a multicenter, retrospective analysis of 66 patients diagnosed with VEXAS syndrome treated with HMA (n = 35) or alloHSCT (n = 31). Baseline characteristics
Saubia Fathima, Margaret Mei‐Kay Wong, Jesus Gonzalez‐Lugo, Susan M. Geyer, Ali Alsugair, Maria Sirenko, Kimberly J. Langer, Terra L. Lasho, Christy Finke, Jun Choi, Maher Abdul‐Hay, Gary Ho, Mark R. Litzow, Aasiya Matin, Urshila Durani, Mehrdad Hefazi, William J. Hogan, Mithun V. Shah, Aref Al‐Kali, Kebede H. Begna, Naseema Gangat, Antoine N. Saliba, Ronald S. Go, Tariq Kewan, Gabriel Bartoo, Jade Kutzke, Kristen McCullough, Kenneth J. Warrington, Megan Sullivan, Kaaren K. Reichard, Horatiu Olteanu, Hemant Murthy, Talha Badar, Yael Kusne, Jeanne Palmer, Saurabh Chhabra, Nathan Punwani, Mary Riwes, Joseph P. McGuirk, Elizabeth F. Krakow, Amelia Langston, Taxiarchis Kourelis, David Dingli, James Foran, Matthew J. Koster, Mrinal M. Patnaik, David B. Beck, Hassan B. Alkhateeb, Abhishek A. Mangaonkar   +48 more
wiley   +1 more source

Review: Colchicine, current advances and future prospects

, 2010
a toxic natural compound and secondary metabolite commonly produced by plants like Colchicum autumnale and Gloriosa superba. It is originally used to treat rheumatic complaints, especially gout, and still finds its uses for these purposes today despite ...
Ravindra Ade, Mahendra Kumar Rai
core  

Biomimetic Nanoparticle Delivering Colchicine to Target Endothelial Inflammation for Atherosclerosis Treatment

Advanced NanoBiomed Research, Volume 6, Issue 9, September 2026.
Platelet membrane‐coated layered double hydroxide nanoparticles were engineered to target inflamed endothelium at early‐stage atherosclerosis and enhance therapeutic efficacy. The biomimetic platform improves stability, immune escape, and inflamed vascular cell targeting, resulting in reduced oxidative stress and downregulated adhesion molecules.
Xiuwen Zhang, Lingqing Zong, Ashish Misra, Sanjay Patel, Zi Gu   +4 more
wiley   +1 more source